Brenzys is not covered on the Reformulary. Reformulary Group has selected specific etanercept biosimilar to be covered: ERELZI, manufactured by Sandoz, a division of Novartis Canada. ERELZI is considered a preferred etanercept biosimilar as it offers the same clinical value at a lower net cost to the plan. ERELZI requires Special Authorization.
